CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Sep. 27, 2020	Dec. 31, 2019
Assets
Cash and cash equivalents		$ 1,587	$ 1,305
Short-term investments		8,912	8,525
Restricted short-term investments		11,413	0
Trade accounts receivable, less allowance for doubtful accounts: 2020—$533; 2019—$527		10,012	8,724
Inventories	[1]	9,295	8,283
Current tax assets		4,000	3,344
Other current assets		2,519	2,622
Total current assets		47,739	32,803
Equity-method investments		15,949	17,133
Long-term investments		3,059	3,014
Property, plant and equipment, less accumulated depreciation: 2020—$16,636; 2019—$16,789		14,403	13,967
Identifiable intangible assets, less accumulated amortization	[2]	30,927	35,370
Goodwill		59,902	58,653
Noncurrent deferred tax assets and other noncurrent tax assets		2,649	2,099
Other noncurrent assets		4,355	4,450
Total assets		178,983	167,489
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2020—$2,149; 2019—$1,462		13,363	16,195
Trade accounts payable		4,141	4,220
Dividends payable		2,112	2,104
Income taxes payable		1,430	980
Accrued compensation and related items		2,425	2,720
Other current liabilities		10,683	11,083
Total current liabilities		34,154	37,304
Long-term debt		49,785	35,955
Pension benefit obligations, net		5,350	5,638
Postretirement benefit obligations, net		1,087	1,124
Noncurrent deferred tax liabilities		4,542	5,578
Other taxes payable		11,720	12,126
Other noncurrent liabilities		6,851	6,317
Total liabilities		113,487	104,042
Commitments and Contingencies
Preferred stock		0	17
Common stock		470	468
Additional paid-in capital		88,161	87,428
Treasury stock		(110,980)	(110,801)
Retained earnings		100,284	97,670
Accumulated other comprehensive loss		(12,676)	(11,640)
Total Pfizer Inc. shareholders’ equity		65,259	63,143
Equity attributable to noncontrolling interests		236	303
Total equity		65,495	63,447
Total liabilities and equity		$ 178,983	$ 167,489

[1] The change from December 31, 2019 reflects increases for certain products, including inventory build for new product launches, market demand, supply recovery and network strategy, and an increase due to foreign exchange.

[2] The decrease is primarily due to amortization, the $900 million impairment of IPR&D, and measurement period adjustments related to the acquisition of Array.